PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 5, 2026Current Cardiology Reports0 citations

Beyond the ICD: Navigating Ventricular Tachycardia Suppression Strategies in the Modern Era

View Full Paper
TBThomas BassoAAAmir AbdelWahabJSJohn L. Sapp

Key Result

Catheter ablation is superior to antiarrhythmic drug therapy for reducing ventricular tachycardia recurrence in patients with ischemic heart disease, although long-term recurrence rates remain high.

Key Points

  • The review aims to evaluate and summarize strategies for suppressing ventricular tachycardia in patients with implantable cardioverter defibrillators.
  • Reviewed recent evidence on ventricular tachycardia management strategies.
  • Highlighted the efficacy of catheter ablation compared to antiarrhythmic drug therapy.
  • Discussed the challenges of achieving long-term suppression and the need for multiple methods.
  • Catheter ablation is superior to antiarrhythmic therapies in reducing VT recurrence in ischemic heart disease patients.
  • Acute freedom from ventricular tachycardia is often achieved, but long-term recurrence rates are high.
  • Multiple suppression techniques may be required due to challenges in long-term VT control.

Structured PICO

What are the current evidence and modalities for ventricular tachycardia suppression in patients with an ICD?

P
Population
Patients with an implantable cardioverter defibrillator (ICD) and ventricular tachycardia (VT)
I
Intervention
Ventricular tachycardia suppression strategies, including catheter ablation and antiarrhythmic drug therapy
O
Outcome
Ventricular tachycardia recurrencehard clinical

Catheter ablation offers improved acute success and is superior to antiarrhythmic drugs for VT suppression in ischemic heart disease, though achieving long-term freedom from VT remains challenging.

Abstract

Purpose of Review Management of patients with an implantable cardioverter defibrillator (ICD) and ventricular tachycardia (VT) is a common clinical challenge. Suppression is often warranted. Catheter ablation (CA) is being used increasingly with expanding indications, and novel procedural strategies are being investigated for refractory cases. The purpose of the review is to synthesize the evidence for ventricular tachycardia suppression and the modalities. Recent Findings Patients with ventricular tachycardia are at increased risk of recurrent events and higher mortality; the risk increases with more events. Catheter ablation is superior to antiarrhythmic drug therapy to reduce VT recurrence in the ischemic heart disease cohort. Acute freedom from VT is typically achievable, but long-term recurrence rates remain high. Summary There has been an expanding role for interventional approaches to VT suppression with improvement in acute success. Achieving long-term VT freedom is difficult, and multiple suppression methods may be needed.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Basso et al. (2026) conducted a review in Ventricular tachycardia in patients with an implantable cardioverter defibrillator. Catheter ablation vs. Antiarrhythmic drug therapy was evaluated on Ventricular tachycardia recurrence. Catheter ablation is superior to antiarrhythmic drug therapy for reducing ventricular tachycardia recurrence in patients with ischemic heart disease, although long-term recurrence rates remain high.

synapsesocial.com/papers/6a226c3e763171746d5486eehttps://doi.org/10.1007/s11886-026-02380-6
Ask AI
Helpful
Bookmark
Share
View Full Paper